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Metabolic effects of adenosine on regional 
myocardial ischemia by phosphorus 31 
nuclear magnetic resonance spectroscopy 
The metabolic effects of adenosine on regionally ischemic myocardium were investigated in an 
open-chest rabbit model by means of phosphorus 31 nuclear magnetic resonance (NMR) 
spectroscopy. Sixteen anesthetized New Zealand white rabbits were subjected to thoracotomy; a 
reversible snare occluder was placed around a large branch of the left circumflex coronary 
artery, and an NMR surface coil was positioned adjacent to the myocardium perfused by this 
vessel. The animals were placed in a 2.0 T CSI spectrometer (GE Medical Systems, Fremont, 
Calif.), and baseline spectra were acquired. Eight animals were treated with intravenous 
adenosine (25 mglkg), and eight rabbits sewed as control subjects. All animals were subjected 
to a lo-minute period of ischemia followed by a period of reperfusion. NMR spectra were 
acquired during both intervals. During the occlusion period, expected increases in inorganic 
phosphate levels and decreases in phosphocreatine levels were observed in both groups; 
however, inorganic phosphate increased less in adenosine-treated animals (adenosine: 
33 rlr 2.8% total spectral area during occlusion vs control: 41 + 3.1%) and phosphocreatine 
diminished less with adenosine (adenosine: 26 + 3% vs control: 13 + 1.2%; p < 0.002). No 
significant differences were seen in ,&adenosine triphosphate levels. In both groups the 
metabolite levels during reperfusion recovered to near baseline values, although 
phosphocreatine remained slightly higher in the treated group during early reperfusion. An 
apparent cardioprotective effect of adenosine on relative phosphocreatine and inorganic 
phosphate levels can be observed in intact rabbits by means of phosphorus 31 NMR 
spectroscopy. (AM HEART J 1992;124:1205.) 
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Depletion of high-energy phosphates is a well-known 
phenomenon that occurs during experimental myo- 
cardial ischemia and reperfusi0n.l In studies corre- 
lating levels of high-energy phosphates with myocar- 
dial contractility, a loss of high-energy phosphates 
(phosphocreatine and adenosine triphosphate) dur- 
ing ischemia, along with a concomitant increase in 
inorganic phosphate levels, is associated with loss of 
contractile function.2, 3 On the other hand, relative 
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preservation of adenosine triphosphate (ATP) dur- 
ing ischemia and reperfusion is associated with 
reversible myocardial injury.4 Phosphorus 31 nuclear 
magnetic resonance (NMR) spectroscopy is a non- 
tissue-destructive method for measuring the relative 
concentrations of high-energy phosphates in intact 
myocardium during ischemia and reperfusion. Re- 
sults of previous studies in intact animals with the 
use of NMR spectroscopy have demonstrated the 
expected changes in high-energy phosphate metabo- 
lism during ischemia and reperfusion, including a 
profound depletion of phosphocreatine, a decrease in 
ATP, and a concomitant increase in inorganic phos- 
phate with a return toward baseline of these values 
on reperfusion of viable myocardium.5-7 31P NMR 
studies can thus provide information regarding cell 
viability during ischemia and reperfusion and can 
help assess the effects of various interventions on is- 
chemic and reperfused myocardium.4+ 8, g 
Adenosine has been shown to reduce myocardial 
injury after prolonged periods of ischemia and to 
1205 
1206 Marcovitz et al. 
Begin Adenosine 
or saline 
0 10 20 30 40 50 
Time (minutes, approximate) 
Fig. 1. Time line showing experimental protocol. 
60 
November 1992 
American Heatl Journal 
limit infarct size.1°-12 The mechanism by which 
adenosine exerts its cardioprotective effect is as yet, 
speculative. The compound is a potent vasodilator 
and may play a role in autoregulation of coronary ar- 
tery flow. It also has an indirect negative inotropic 
effect.13 One can speculate that adenosine might play 
a role in decreasing degradation or increasing reple- 
tion of high-energy phosphates through the provision 
of precursors for ATP synthesis. Finally, the agent 
may exert a beneficial effect by acting on neutrophils 
to limit reperfusion injury.14 
NMR studies to date have examined the cardio- 
protective effects of adenosine in the isolated per- 
fused heart15; however, to our knowledge no 31P 
NMR studies have examined the protective effects of 
adenosine in the intact animal model. Because iso- 
lated heart preparations may behave differently 
metabolically from the intact myocardium, it is im- 
portant to examine the metabolic changes seen dur- 
ing ischemia and reperfusion in intact animals. In 
addition, previous studies with adenosine in the in- 
tact animal model, in which biochemical and histo- 
pathologic techniques were used, have generally ex- 
amined its cardioprotective effects during prolonged 
(90 minutes or more) periods of ischemia.lO-l2 Few 
studies have considered the actions of adenosine 
during a brief period of ischemia comparable to that 
which would result in myocardial stunning. Accord- 
ingly this study was undertaken to examine whether 
adenosine would provide a beneficial effect on high- 
energy phosphate metabolism as measured by 31P 
NMR spectroscopy during a brief period of ischemia 
and reperfusion in intact animals. 
METHODS 
Sixteen New Zealand white rabbits weighing 3 to 5 kg 
were anesthetized with xylazine (10 mg/kg) and ketamine 
(40 mg/kg) via intramuscular injection. The internal jugu- 
lar vein was cannulated for maintenance of anesthesia with 
small boluses of pentobarbital (0.2 to 0.5 cc) and for intra- 
venous infusion of adenosine or normal saline solution. The 
animals underwent tracheal intubation and were placed on 
a Harvard rodent ventilator (Harvard Apparatus, Inc., 
South Natick, Mass.) with a mixture of 95% oxygen and 
5 CO carbon dioxide. The anesthetized animals underwent 
thoracotomy. A reversible snare occluder consisting of 6-O 
suture threaded through a small plastic catheter was placed 
around a large marginal branch of the left circumflex cor- 
onary artery. During occlusion the catheter was slid down 
onto the surface of the artery to produce occlusion and held 
in place with a plastic clip. A four-turn 13 mm solenoidal 
radiofrequency coil was sutured onto the epicardial surface 
over the region of myocardium to be rendered ischemic. 
The animals were then placed in the bore of a General 
Electric 2.0 T CSI spectrometer (GE Medical Systems, 
Fremont Calif.). Shimming was performed on the proton 
signal, yielding a line width of three to five parts per mil- 
lion for the water peak. Ten rabbits were studied with ECG 
gating and six rabbits with respiratory gating, which was 
found to reduce line-broadening motion artifact. At the 
onset of the experiment, baseline spectra were obtained 
over a lo-minute period by averaging 256 spectral acquisi- 
tions. After baseline spectra were obtained, an infusion of 
adenosine (25 mg/kg), 2 mg/min, or normal saline solution 
was begun. After a lo-minute equilibration period, a sec- 
ond baseline reading was obtained. The snare was then 
tightened around the coronary artery to produce occlusion, 
and another spectrum was obtained. The snare was then 
loosened to allow reperfusion, and two more spectra were 
obtained consecutively at lo-minute intervals. A diagram 
of the protocol is shown in Fig. 1. 
Ten-Hertz line broadening was used to filter the spec- 
trum, and phasing was carried out with a computer 
program with manual correction performed as needed. The 
areas under five peaks corresponding to inorganic phos- 
phate, phosphocreatine, y-, N-, and @-ATP were deter- 
mined by means of a Lorentzian peak-fitting program 
(NMRl, New Methods Research, Inc., Syracuse, N.Y.). In- 
dividual peak areas were expressed as percentages of total 
peak area of the inorganic phosphate, phosphocreatine, 
and three ATP peaks. The phosphocreatine:inorganic 
phosphate ratio was also calculated. pH was calculated 
from the shift of inorganic phosphate during ischemia in 
relation to phosphocreatine as previously described.“j Ex- 







Fig. 2. Mean heart rates of the two groups are shown. Er- 
ror bars are standard deviations. For technical reasons, 
heart rates were not obtained from all animals, particularly 
those animals in which respiratory rather than ECG gating 
was used (n = 5 for control group; n = 6 for treatment 
group). 
error of the mean. Statistical analysis was performed with 
unpaired Student’s t test. 
RESULTS 
Heart rates are shown in Fig. 2. As noted, rate data 
were not collected from all animals for technical rea- 
sons, particularly when respiratory rather than car- 
diac gating was used. The heart rate decreased 
slightly in adenosine-treated animals during the oc- 
clusion and reperfusion periods, and averaged ap- 
proximately 20% lower than in the control group. 
Represent,ative spectra are shown in Fig. 3. The pH 
measured during coronary occlusion did not differ 
between adenosine-treated and control animals (Fig. 
4). The pH was not measured during reperfusion, 
since it was difficult to accurately measure the shift 
in inorganic phosphate resulting from the small size 
and spectral contamination of the inorganic phos- 
phate peak, which probably contains contributions 
from phospho-, mono-, and diesters, as well as 
2,3-diphosphoglycerate (DPG). 
Levels of phosphocreatine decreased significantly 
with occlusion in both groups (Fig. 5). In the adenos- 
ine-treated group, however, the decrease was much 
less pronounced than in the control group (phos- 
phocreatine levels during occlusion were 26 + 3 % in 
the treatment group compared with 13 -+ 1.2 5% in the 
control group, p < 0.002). With reperfusion, phos- 
phocreatine values returned to baseline in both 
groups but tended to remain higher in the adenosine- 
treated group during the first reperfusion period 
(38 +- 3.2% as compared with 30 -+ 2.5%; p < 0.10). 
By the second reperfusion period, there were no sig- 
nificant differences between the adenosine-treated 
and control groups. 
Inorganic phosphate levels increased significantly 
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Fig. 3. Representative spectra obtained during baseline, 
occlusion, and reperfusion periods. Spectra are shown af- 
ter phasing and baseline correction. 
during occlusion in both groups; however, the mag- 
nitude of this increase during occlusion was less in the 
adenosine-treated group than in the control group 
(33 t 2.8% for treated animals vs 41 -I- 3.1% for 
control animals; p = 0.06). Both returned to normal 
during reperfusion, and there were no significant dif- 
ferences in inorganic phosphate levels by the end of 
reperfusion (Fig. 6). 
Fig. 7 depicts p-ATP levels during baseline, occlu- 
sion, and both reperfusion periods. There were no 
significant differences between the treated and non- 
treated groups with regard to /3-ATP levels during 
occlusion and reperfusion. The phosphocreatine: 
inorganic phosphate ratio, an indicator of mitochon- 
drial function, was calculated at baseline, occlusion, 
and both reperfusion periods (Fig. 8). This ratio was 
significantly higher in the adenosine-treated group 
than in the control group during occlusion, with 
evidence of a similar trend during reperfusion. 
DISCUSSION 
In this investigation, decreases in high-energy 
phosphate, phosphocreatine, and ATP levels were 
observed during a brief reversible period of regional 
myocardial ischemia, with a return toward baseline 
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Fig. 4. pH data during occlusion are shown (mean t 
SEM). 
Fig. 5. Relative peak areas for phosphocreatine peaks, 
expressed as percentage of total peak area, are shown 
(mean -t SEM). 
values of these compounds during reperfusion. The 
depletion of phosphocreatine and ATP was less pro- 
nounced in the adenosine-treated group compared 
with the control group. A concomitant increase in in- 
organic phosphate levels was seen with occlusion in 
both groups but was of a greater magnitude in the 
control group. Although the effects of adenosine on 
high-energy phosphate levels was most evident dur- 
ing ischemia, there was a trend toward increased 
phosphocreatine levels in the adenosine-treated 
group during early reperfusion. We note that our 
measurements represent an average of signal from all 
myocardium proximate to the coil. Hence the obser- 
vations may be a result of differences in both the size 
of the ischemic zone and differences in high-energy 
phosphate levels within the ischemic tissue. 
There are several possible mechanisms for these 
apparent cardioprotective effects. These include in- 
creased coronary arterial flow, reduced myocardial 
oxygen demand as a result of the negative inotropic 
effects of adenosine, inhibition of reperfusion injury, 
and possibly a metabolic role in improved ATP syn- 
thesis or decreasing ATP degradation consequent to 
the role of adenosine as a metabolic intermediate. 
The present study does not allow us to distinguish 
among these possible mechanisms. 
Previous reports have demonstrated beneficial ef- 
fects of adenosine on the myocardium during reper- 
fusion after ischemic injury. In the majority of these 
studies, the compound was administered during 
reperfusion. Olaffson et al.iO observed a significant 
reduction in infarct size in adenosine-treated animals 
after a go-minute period of coronary occlusion, with 
preservation of endothelial structure and less neu- 
trophilic infiltration in the subendocardial regions of 
injured zones. Likewise Babbit et all1 observed im- 
proved regional myocardial blood flow and improved 
ventricular function in animals treated with intra- 
coronary adenosine 3 hours after reperfusion follow- 
ing a 2-hour period of ischemia. In adjacent trans- 
murally injured zones, there was evidence of reduced 
injury to the microvasculature. In a later study sim- 
ilar cardioprotective effects of intravenous adenosine 
on infarct size and ventricular function were seen 
after 90 minutes of occlusion17; however, in a third set 
of experiments involving a longer 3-hour period of 
ischemia, no beneficial effects of adenosine adminis- 
tration on infarct size or regional wall function were 
observed.18 Thus the cardioprotective effects of aden- 
osine may be dependent on the duration of the 
ischemic insult and may be limited by a lengthy pe- 
riod of severe ischemia. A similar cardioprotective 
effect has been reported in rabbits. In one experiment 
consisting of a 30-minute occlusion of an obtuse 
marginal branch of the left circumflex artery followed 
by a lengthy 48-hour reperfusion period, adenosine 
administered during early reperfusion was shown to 
reduce infarct size in comparison with that in control 
animals.lg 
In a study by Hoffmeister et al.,zO adenosine was 
infused via the intracoronary route in a series of dogs 
during a reperfusion period that followed a 45 
minute period of coronary occlusion. The adenosine 
enhanced the repletion of high-energy phosphates in 
the tissues but interestingly did not improve ventric- 
ular function, suggesting that myocardial stunning 
may be related to other mechanisms. A number of 
experiments have been performed on isolated heart 
preparations; most 21-24 but not a1125 document a ben- 
eficial effect for adenosine administration. A study by 
Bolling et a1.24 involving isolated adult rabbit hearts 
showed that adenosine improved myocardial adeno- 
sine levels but not ATP levels during ischemia. Dur- 
ing recovery the compound improved functional re- 
covery and ATP levels. The differences between 
these results and ours may be a consequence of the 
substantial differences between isolated heart mod- 
els and intact animals or may be due to the fact that 
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Fig. 6. Relative peak areas for inorganic phosphate peaks, 
expressed as percentage of total peak area, are shown 
(mean k SEM). See text for discussion of potential errors 
in determination of these peaks when they are small, that 
is, outside of occlusion period. 
our surface coil sampled a larger area of myocardium 
than the biopsy specimens described in this report. 
In most of the studies cited thus far, adenosine has 
been shown to have a beneficial effect on myocardial 
ATP levels, ventricular function, or both. In many of 
these studies, the agent is given after the ischemic 
insult; therefore, a mitigating effect of adenosine on 
reperfusion injury is suggested. Adenosine is believed 
to prevent cytotoxic changes through inhibition of 
neutrophil aggregation and adherence, neutrophil- 
mediated generation and release of superoxide anion, 
and release of degradative enzymes including my- 
eloperoxidase, p-glucuronidase, and lysozyme.14T 26-2g 
These actions of adenosine suggest that one effect 
may be prevention of the inflammatory response once 
injury has taken place. In the studies of Olaffson et 
al.1° and Babbit et al.,” evidence of decreased infil- 
tration of leukocytes in ischemic areas with attenu- 
ated cellular edema, preservation of the microvascu- 
lature, and a concomitant increase in blood flow was 
observed in ischemic areas after reperfusion. Thus a 
mechanism of cardioprotection was suggested to be 
the limitation of the deleterious changes associated 
with reperfusion injury and progression of the “no- 
reflow” phenomenon. 
In the present study no significant differences were 
observed between the treated and control groups 
during reperfusion. One possible explanation is the 
limited sensitivity of our measurement technique. 
Biological explanations for this failure include the 
fact that t,he reperfusion period in our study may 
have been too short for metabolic differences to be 
observed. Although it is generally believed that 
reperfusion injury begins with the hyperemic re- 
sponse immediately after the release of coronary oc- 
clusion, a longer reperfusion time than the one used 











Fig. 7. Relative peak areas for ATP peaks, measured from 
P-peak and expressed as percentage of total peak area, are 
shown (mean + SEM). 
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Fig. 6. Calculated peak area ratios of phosphocreatine 
over inorganic phosphate are shown (mean 2 SEM). 
these changes to be observed.30-32 Differences in the 
length of ischemia might also explain the disparate 
results. We used a short period of ischemia (10 min- 
utes). Although it is well accepted that a zone of is- 
chemia progresses from subendocardium to subepi- 
cardium beginning after approximately 5 minutes of 
coronary occlusion in rabbits, subendocardial infarc- 
tion is not produced until 15 minutes of occlusion.33 
Long periods of ischemia, perhaps leading to more 
irreversible changes, may allow other benefits of 
adenosine to be observed during the reperfusion pe- 
riod. 
Adenosine is known to be a potent dilator of cor- 
onary resistance vessels. 131 31 One possible mecha- 
nism by which adenosine serves to protect high-en- 
ergy phosphate metabolism during ischemia could be 
through improved coronary blood flow, either di- 
rectly via dilation of resistance vessels or indirectly 
through augmentation of collateral flow; this mech- 
anism was suggested by Ledingham et a1.23 Enhanced 
oxygen delivery to ischemic areas could help main- 
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tain the overall balance between oxygen supply and gesting that treatment with agents that salvage 
demand; however, in previous experiments in this high-energy phosphate synthesis before ischemia 
laboratory, injection of microspheres demonstrated may have beneficial effects that extend beyond 
little or no myocardial blood flow to ischemic regions increasing energy stores for metabolic processes 
with the use of this intact rabbit model during coro- alone. Clearly, the full range of cardioprotective 
nary occlusion5 effects of adenosine has not yet been fully elucidated. 
Another property of adenosine that may contrib- 
ute to its cardioprotective effect is its antiadrenergic 
action.33-35 Antiadrenergic action may decrease my- 
ocardial oxygen demand during ischemia, thus con- 
tributing to preservation of high-energy phosphates. 
This negative inotropic and chronotropic effect offers 
one possible explanation for our findings. Rabbits 
treated with adenosine averaged a 20% lower heart 
rate at baseline, during ischemia, and on reperfusion, 
suggesting a clear trend toward relative bradycardia. 
Several studies have investigated a possible car- 
dioprotective effect of adenosine arising from its role 
as a metabolic precursor of ATP. Mauser et a1.36 
demonstrated a go-fold increase in adenine nuclide 
de novo synthesis and increased tissue ATP levels 
with the administration of adenosine during reper- 
fusion in postischemic myocardium in dogs. Results 
of experiments conducted by Foker et a1.37 in dogs 
subjected to cardiopulmonary bypass also suggest 
that adenosine, when administered with an inhibitor 
of adenosine catabolism, enhanced the recovery of 
myocardial ATP levels after termination of the 
bypass. Consistent results have been obtained in an- 
other investigation through administration of aden- 
osine deaminase, which catabolizes adenosine. Iso- 
lated hearts receiving this enzyme during ischemia 
showed decreased functional recovery and lower 
ATP levels, whereas hearts treated with adenosine 
showed increased function and higher ATP levels.38 
Similarly, in a study of open-chest dogs, treatment 
with an inhibitor of adenosine catabolism protected 
contractile function after 15 minutes of ischemia.3g 
There has been at least, one prior investigation in 
which 31P NMR spectroscopy was used to character- 
ize the effects of adenosine on ischemic myocardium. 
In an isolated guinea pig heart model, preservation of 
high-energy phosphates during ischemia, with accel- 
erated resynthesis of ATP during several hours of 
reperfusion by means of treatment with adenosine, 
was observed.15 In this study, preservation of high- 
energy phosphates was associated with preserved 
myocardial function. Our own results are consistent 
with those of most previous investigat.ions and are 
significant in that they confirm the enhanced high- 
energy phosphate levels in an intact animal model of 
regional ischemia. We observed the beneficial effects 
during the ischemic period, and there was also a trend 
toward improved high-energy phosphate levels dur- 
ing reperfusion. Intact animal models are clearly 
more physiologic than isolated heart preparat.ions, 
and the real-time NMR technique is different from 
and hence complementary to biopsy techniques. 
The NMR method samples a larger area of myocar- 
dium, and measures both relative phosphocreatine 
and ATP levels, so there is no possibility that ATP 
degradation can be obscured between biopsy and 
assay. 
Maintaining levels of high-energy phosphates for 
normal cellular metabolic processes may play a role 
in cardioprotection, since these are energy-depen- 
dent processes that depend on adequate stores of 
ATP. Adenosine may either decrease degradation of 
ATP or enhance reconstitution of ATP via synthetic 
pathways, preserving the metabolic functions of the 
cell and limiting myocardial injury. In a recent study 
by Gruber et a1.,40 using pretreatment with &amino- 
4-imidazole carboxamide-riboside in intact animals 
to enhance concentrations of endogenous adenosine 
during ischemia, treatment groups showed an in- 
crease in endogenous adenosine only during net hy- 
drolysis of ATP.40 Treatment groups were also found 
to have increased regional myocardial blood flow and 
f’ewer ventricular arrhythmias during ischemia, sug- 
The present study has several limitations. We only 
measured high-energy phosphate levels and did not 
assess ventricular function or the size of the zone of 
ischemic myocardium. Some but not all of the previ- 
ously cited investigations show discordance between 
high-energy phosphate levels and ventricular funt- 
tion. It is also possible that our slP NMR imaging 
technique, which required several minutes of acqui- 
sition time, was not adequately sensitive to detect, 
small or transient changes in high-energy phosphate 
levels during a brief period of reperfusion. Moreover, 
there are well-known difficulties with this model re- 
lated to the signal-to-noise ratio, which may make it 
difficult to detect smaller changes. Although the gross 
effects of coronary occlusion were observed on release 
of coronary occlusion, it would have been helpful t.o 
look at the histologic and biochemical evidence of 
reperfusion injury after a brief period of ischemia. 
The addition of biochemical markers of neutrophil 
activity might have added to the sensitivity of this 
model in yielding insights into the cardioprotective 
effects of adenosine and various interventions during 
a brief period of ischemia. 
Volume 124 
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Several known limitations of magnetic resonance 
methodology should be stated briefly, inasmuch as 
they influence the interpretation of the quantitative 
data. We did not perform a saturation correction on 
the peak areas; hence relative peak areas of different 
metabolites as reported here will not be equally pro- 
portional to the respective metabolite concentra- 
tions. Thus our ratios may differ from the corrected 
results reported by others. There is substantial over- 
lap between spectral peaks, particularly in the crucial 
inorganic phosphate region. There may also be spec- 
tral contamination of the inorganic phosphate reso- 
nance by 2,3-DPG in the blood. These factors will re- 
duce the accuracy of our inorganic phosphate mea- 
surements. The spectral phasing, baseline correction, 
and peak fitting techniques used have known limita- 
tions as we1L4i Spectral localization was achieved by 
the proximity of the myocardium to the surface coil; 
thus, partial volume effects between ischemic and 
nonischemic myocardium are possible. Differences in 
high-energy phosphate levels may reflect both dif- 
ferences in tissue levels in ischemic myocardium and 
differences in the size of the ischemic zone. The ob- 
ject of these experiments was to detect differences 
between adenosine-treated and control groups. Inas- 
much as the same acquisition and analysis parame- 
ters were used in both groups, these limitations are 
not expected to change the validity of the intergroup 
comparisons. 
This study did not address the long-term effects of 
a brief period of &hernia or the long-term efficacy of 
adenosine. Since changes in phosphocreatine levels 
of borderline significance during early reperfusion 
were noted in rabbits treated with adenosine, it is 
possible that additional studies utilizing longer peri- 
ods of reperfusion would detect significant differ- 
ences in high-energy phosphate levels during reper- 
fusion. In conclusion, we used NMR spectroscopy to 
compare myocardial high-energy phosphate metab- 
olites in regionally ischemic myocardium in rabbits 
with and without treatment with adenosine. Adeno- 
sine preserved high-energy phosphate levels during 
severe ischemia but in our in vivo model did not alter 
high-energy phosphate levels during early reperfu- 
sion. Our metabolic data suggest that adenosine in- 
tervention during myocardial ischemia may be car- 
dioprotective and limit ischemic injury. 
We thank the General Electric Company for their support of the 
CSI facility. 
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